Eva Meluzínová
- Co-authors
- Eva HavrdováKlaus SchmiererLudwig KapposMefkûre EraksoyTarek YousryDavid MacManusRalf GoldVolker Limmroth
- Topics
- Multiple Sclerosis Research Studies (19 papers)Polyomavirus and related diseases (5 papers)Immunotherapy and Immune Responses (3 papers)
- Partner nations
- CzechiaUnited StatesSwitzerland
In The Last Decade
Eva Meluzínová
19 papers receiving 580 citations
Peers
Comparison fields: 5 of 84
- Pathology and Forensic Medicine 404
- Molecular Biology 169
- Oncology 146
- Neurology 130
- Immunology 130
Countries citing papers authored by Eva Meluzínová
This map shows the geographic impact of Eva Meluzínová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Meluzínová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Meluzínová more than expected).
Fields of papers citing papers by Eva Meluzínová
This network shows the impact of papers produced by Eva Meluzínová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Meluzínová. The network helps show where Eva Meluzínová may publish in the future.
Co-authorship network of co-authors of Eva Meluzínová
This figure shows the co-authorship network connecting the top 25 collaborators of Eva Meluzínová. A scholar is included among the top collaborators of Eva Meluzínová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Meluzínová. Eva Meluzínová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 12 | |
| 2 | 3 | |
| 3 | 4 | |
| 4 | 8 | |
| 5 | 0 | |
| 6 | 0 | |
| 7 | 12 | |
| 8 | 1 | |
| 9 | 22 | |
| 10 | 33 | |
| 11 | Alemtuzumab v léčbě roztroušené sklerózy | 0 |
| 12 | Kvalita života pacientů s roztroušenou sklerózou mozkomíšní | 0 |
| 13 | Dimethyl-fumarát v léčbě relabující-remitující formy roztroušené sklerózy | 0 |
| 14 | 5 | |
| 15 | 54 | |
| 16 | 37 | |
| 17 | The effect of BG00012 on conversion of gadolinium-enhancing lesions to T1-hypointense lesions | 2 |
| 18 | 375 | |
| 19 | Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study | 13 |
| 20 | BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis | 11 |
About Eva Meluzínová
Eva Meluzínová is a scholar working on Pathology and Forensic Medicine, Developmental Neuroscience and Gastroenterology, having authored 29 papers that have together received 601 indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (19 papers), Polyomavirus and related diseases (5 papers) and Immunotherapy and Immune Responses (3 papers). The work is most often cited by research in Pathology and Forensic Medicine (404 citations), Neurology (130 citations) and Biological Psychiatry (18 citations). Eva Meluzínová has collaborated with scholars based in Czechia, United States and Switzerland. Frequent co-authors include Eva Havrdová, Klaus Schmierer, Ludwig Kappos, Mefkûre Eraksoy, Tarek Yousry, David MacManus, Ralf Gold, Volker Limmroth, Chris H. Polman and Gilmore O’Neill. Their work appears in journals such as The Lancet, PLoS ONE and Journal of the American Academy of Dermatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.